Table 4.

Patients with karyotypic abnormalities in Ph−cells

Patient
no.		Age at
diagnosis,
y		SexTreatment
prior to
imatinib		Best
response
prior to
imatinib		Disease
duration
prior
to
imatinib,
mo		Disease
phase
at
starting
imatinib		Best
response
to
imatinib		Time
to
detection
of
abnormality,
mo		MDSSurvival
from
diagnosis,
mo		Initial
karyotype		Karyotype
at best
response prior
to imatinib		Karyotype
prior to
imatinib		First karyotype
with abnormalities
in Ph− cells
15 43 F IFN, HU PHR 10 AP CCR 15 Yes Allograft 26 46XX t(9;22)[20] 46XX,t(9;22),t(12;16)[33] 46XX,t(9;22),t(12;16)[20] 46,XX[29]/45XX,−7[28]/
46,XX,t(9,22),t(12,16)[1] 
19 68 F IFN, HU mCR 29 mCR MCR 12 No 54+ 46XX t(9;22)[25] ND 30/50 BCR-ABL (HMF);
0/50 +8 (HMF) 		46XX[11]/46,XX,
t(9;22)[3]/47,XX,+8[8] 
33 46 F Ara-C, HU,
Ida, IFN 		CHR 23 CP CCR 12 No 47+ 46,XX,t(6;9;22)
(q22;q34;q11)
[25] 		46,XY,t(6;9;22)[25] 46,XX,t(6;9;22)[25] 46,XX,t(6;9;22)[13]/
46,XX[8]/46,XX,ider(20)
(q10)t(20;21)(q22;q22)[4] 
34 48 M Ida, Ara-C,
HU, IFN 		CCR 17 CP CCR 9 Yes 43+ 46XX t(9;22)[17] ND 46,XX,t(9;22)[25];
0/35 t(3;21) (HMF);
1/300 t(3;21) (IPF) 		46XY[4]/46,XY,
t(3;21)(q27?;q22)[15] 
47 40 M Ida, Ara-C,
HU, IFN,
Bu (ABMT) 		MCR
(leukapheresis
product) 		67 CP CCR 3 No 96+ ND 46,XY,t(9;22)[5]/46,XY[24] 46,XY,t(9;22)[25];
0/50 del(20) (HMF);
11/500 del(20) (IPF) 		46,XY[9]/46,XY,
t(9;22)[6]/46,XY,del(20q)[5] 
51 70 M HU PHR 14 AP MCR 6 No 31+ ND ND 46,XY,t(9,22)[24]/47,
XY,t(9,22),+der
(22)[1];0/100-Y(IPF) 		46,XY[6]/45,X-Y[2]/
46,XY,t(9;22)[1] 
52 56 M IFN, HU PHR 36 CP CCR 6 No 68+ 46XX t(9;22)[30] ND 46,XY,t(9;22)[25];
0/500-Y(IPF) 		46,XY[11]/45,X-Y[4] 
53 36 M Ida, Ara-C,
HU, IFN,
Bu (ABMT),
MUD allograft4-150 		CCR4-151 52 MCR CCR 12 No 76+ 46,XY,t(9;22) ND 46,XY[25];0/25
del(20) (HMF);
9/300 del(20) (IPF) 		6,XY[18]/46,XY,t(7;17)
(q11;q21)/del(20q)
[5]/46,XY,t(9;22)[2] 
Patient
no.		Age at
diagnosis,
y		SexTreatment
prior to
imatinib		Best
response
prior to
imatinib		Disease
duration
prior
to
imatinib,
mo		Disease
phase
at
starting
imatinib		Best
response
to
imatinib		Time
to
detection
of
abnormality,
mo		MDSSurvival
from
diagnosis,
mo		Initial
karyotype		Karyotype
at best
response prior
to imatinib		Karyotype
prior to
imatinib		First karyotype
with abnormalities
in Ph− cells
15 43 F IFN, HU PHR 10 AP CCR 15 Yes Allograft 26 46XX t(9;22)[20] 46XX,t(9;22),t(12;16)[33] 46XX,t(9;22),t(12;16)[20] 46,XX[29]/45XX,−7[28]/
46,XX,t(9,22),t(12,16)[1] 
19 68 F IFN, HU mCR 29 mCR MCR 12 No 54+ 46XX t(9;22)[25] ND 30/50 BCR-ABL (HMF);
0/50 +8 (HMF) 		46XX[11]/46,XX,
t(9;22)[3]/47,XX,+8[8] 
33 46 F Ara-C, HU,
Ida, IFN 		CHR 23 CP CCR 12 No 47+ 46,XX,t(6;9;22)
(q22;q34;q11)
[25] 		46,XY,t(6;9;22)[25] 46,XX,t(6;9;22)[25] 46,XX,t(6;9;22)[13]/
46,XX[8]/46,XX,ider(20)
(q10)t(20;21)(q22;q22)[4] 
34 48 M Ida, Ara-C,
HU, IFN 		CCR 17 CP CCR 9 Yes 43+ 46XX t(9;22)[17] ND 46,XX,t(9;22)[25];
0/35 t(3;21) (HMF);
1/300 t(3;21) (IPF) 		46XY[4]/46,XY,
t(3;21)(q27?;q22)[15] 
47 40 M Ida, Ara-C,
HU, IFN,
Bu (ABMT) 		MCR
(leukapheresis
product) 		67 CP CCR 3 No 96+ ND 46,XY,t(9;22)[5]/46,XY[24] 46,XY,t(9;22)[25];
0/50 del(20) (HMF);
11/500 del(20) (IPF) 		46,XY[9]/46,XY,
t(9;22)[6]/46,XY,del(20q)[5] 
51 70 M HU PHR 14 AP MCR 6 No 31+ ND ND 46,XY,t(9,22)[24]/47,
XY,t(9,22),+der
(22)[1];0/100-Y(IPF) 		46,XY[6]/45,X-Y[2]/
46,XY,t(9;22)[1] 
52 56 M IFN, HU PHR 36 CP CCR 6 No 68+ 46XX t(9;22)[30] ND 46,XY,t(9;22)[25];
0/500-Y(IPF) 		46,XY[11]/45,X-Y[4] 
53 36 M Ida, Ara-C,
HU, IFN,
Bu (ABMT),
MUD allograft4-150 		CCR4-151 52 MCR CCR 12 No 76+ 46,XY,t(9;22) ND 46,XY[25];0/25
del(20) (HMF);
9/300 del(20) (IPF) 		6,XY[18]/46,XY,t(7;17)
(q11;q21)/del(20q)
[5]/46,XY,t(9;22)[2] 

PHR indicates partial hematologic remission; mCR, minor cytogenetic remission; and HMF, hypermetaphase FISH. Other abbreviations are explained in Table 1 and the text.

F4-150

2 Gy TBI/fludarabine.

F4-151

Graft rejection and autologous reconstitution in CCR.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal